ArticleFrontiers in pharmacology2019
Susceptibility-Related Factor and Biomarkers of Dietary Supplement
Article in Frontiers in pharmacology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 46 citations in OpenAlex.
- Hepatotoxicity Assessment of Anshenbunao Syrup by Multi-Component Quantification In Vivo/In Vitro and Cell Biological Evaluations.Pharmaceuticals (Basel, Switzerland) · 2026Article
- Phytochemistry, pharmacology, toxicology and detoxification ofFrontiers in pharmacology · 2024Review
- Antitumor effect and metabonomics of niclosamide micelles.Journal of cellular and molecular medicine · 2022Article
- Idiosyncratic liver injury induced by bolus combination treatment with emodin and 2,3,5,4'-tetrahydroxystilbene-2-Frontiers in pharmacology · 2022Article
- Immunostimulatory activity and structure-activity relationship of epimedin B fromFrontiers in pharmacology · 2022Article
- A review of herb-induced liver injury in mainland china.Frontiers in pharmacology · 2022Review
- Icariside I specifically facilitates ATP or nigericin-induced NLRP3 inflammasome activation and causes idiosyncratic hepatotoxicity.Cell communication and signaling : CCS · 2021Article
- Screening for Susceptibility-Related Biomarkers of Diclofenac-Induced Liver Injury in Rats Using Metabolomics.Frontiers in pharmacology · 2021Article
- Susceptibility-Related Cytokine Panel for Prediction ofJournal of inflammation research · 2021Article
- Herb-Induced Liver Injury Related toFrontiers in pharmacology · 2021Review
- Multi-Omics Integration to Reveal the Mechanism of Hepatotoxicity Induced by Dictamnine.Frontiers in cell and developmental biology · 2021Article
- The Immunological Mechanisms and Immune-Based Biomarkers of Drug-Induced Liver Injury.Frontiers in pharmacology · 2021Review
- Lipidomics Analysis Indicates Disturbed Hepatocellular Lipid Metabolism inFrontiers in pharmacology · 2020Article
- Phytochemicals protect L02 cells against hepatotoxicity induced by emodinToxicology research · 2019Article
- Molecular Biomarkers in Drug-Induced Liver Injury: Challenges and Future Perspectives.Frontiers in pharmacology · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.